Table 1 Comparisons of clinical characteristics of pediatric patients with ADVP in the PIBO and non-PIBO groups
Variables | Non-PIBO group (n = 817) | PIBO group (n = 46) | P Value |
|---|---|---|---|
Characteristic | |||
 Male, n (%) | 525 (64.3) | 35 (76.1) | 0.1 |
 Age [M (P25-P75)]/(months) | 13 (11–24) | 12 (11–24) | 0.55 |
Age group (months), n (%) | |||
 < 6 | 55 (6.7) | 3 (6.5) | 0.96 |
 6–24 | 560 (68.5) | 34 (73.9) | 0.44 |
 25–36 | 202 (24.7) | 9(19.6) | 0.43 |
 Allergic constitution [n (%)] | 162 (19.8) | 13 (28.3) | 0.17 |
Sigs and symptoms | |||
 Median duration of hospitalization [M (P25-P75)]/d | 7 (5–10) | 9(6–13) | 0.02 |
 Duration of fever [M (P25-P75)]/d | 7 (5–11) | 18 (11–24) | 0.000 |
 Wheezing [n (%)] | 163(20.0) | 15(32.6) | 0.04 |
Laboratory characteristic | |||
 WBC [M (P25-P75)]/ × 109 L−1 | 7.3 (5.4–10.3) | 7.2 (5.5–9.7) | 0.1 |
 N% [M (P25-P75)]/% | 42.1 (26.8–55.9) | 58.6(48.7–69.9) | 0.000 |
 Hb [M (P25-P75)]/g·L−1 | 111(104–118) | 109 (97–117) | 0.36 |
 PLT [M (P25-P75)]/ × 109 L−1 | 314 (228–417) | 250 (161–313) | 0.02 |
 CRP [M (P25-P75)]/mg·L−1 | 6.5 (3.1–17.9) | 9.8 (3.1–34.5) | 0.10 |
 PCT [M (P25-P75)]/ng·mL−1 | 0.2 (0.07–0.9) | 0.5 (0.2–1.3) | 0.95 |
 LDH [M (P25-P75)]/U·L−1 | 382 (307–517) | 587 (460–768) | 0.00 |
 Fig [M (P25-P75)]/mg·dL−1 | 3.1 (2.4–4.0) | 2.5 (2.0–3.1) | 0.98 |
 DD [M (P25-P75)]/mg·L−1 | 0.7 (0.4–1.6) | 2.0 (0.8–3.3) | 0.026 |
 CK-MB [M (P25-P75)]/ng·mL−1 | 29 (22–42) | 34 (26–45) | 0.81 |
 ALT [M (P25-P75)]/U·L−1 | 19 (14–30) | 29 (20–62) | 0.00 |
 AST [M (P25-P75)]/U·L−1 | 45(36–59) | 90 (61–111) | 0.00 |
 Mixed infection [n (%)] | 564 (69.0) | 34 (73.9) | 0.49 |
 ADV load from BALF, log10 copies/mL | 6.0 (4.3–7.3) | 6.4 (4.9–7.4) | 0.026 |
Humoral immunity [M (P25-P75), %] | |||
 IgG [M (P25-P75)]/g·L−1 | 7.8 (6.4–9.6) | 8.1 (5.9–11.5) | 0.72 |
 IgA [M (P25-P75)]/g·L−1 | 0.7 (0.5–1.2) | 0.9 (0.5–1.3) | 0.99 |
 IgM [M (P25-P75)]/g·L−1 | 1.0 (0.7–1.3) | 0.9 (0.6–1.3) | 0.6 |
Cellular immunity [M (P25-P75), %] | |||
 CD3+ | 52.2 (43.4–60.1) | 57.1 (45.9–63.2) | 0.17 |
 CD3+ CD4+  | 26.4 (19.9–34.4) | 26.3 (19.6–36.5) | 0.58 |
 CD3+ CD8+  | 20.9(17.2–26.4) | 22.7 (17.5–31) | 0.23 |
 Lung consolidation [n (%)] | 302 (37.0) | 27(58.7) | 0.003 |
 Complication [n (%)] | 192 (23.5) | 39 (84.8) | 0.000 |
Treatment, n (%) | |||
 IMV | 38 (4.7) | 30 (65.2) | 0.000 |
 Corticosteroids | 230 (28.2) | 32 (69.6) | 0.000 |
 IV immunoglobulin | 326 (39.9) | 36 (78.3) | 0.000 |
 Tracheoscopy intervention therapy | 245 (30.0) | 29 (63.0) | 0.000 |